Advanced heart failure treated with continuous-flow left ventricular assist device.

  title={Advanced heart failure treated with continuous-flow left ventricular assist device.},
  author={Mark S. Slaughter and Joseph G. Rogers and Carmelo A. Milano and Stuart D. Russell and John V. Conte and David S. Feldman and Benjamin C. Sun and Antone J. Tatooles and Reynolds Delgado and James W. Long and Thomas C. Wozniak and Waqas Ghumman and David J. Farrar and O. Howard Frazier},
  journal={The New England journal of medicine},
  volume={361 23},
BACKGROUND Patients with advanced heart failure have improved survival rates and quality of life when treated with implanted pulsatile-flow left ventricular assist devices as compared with medical therapy. New continuous-flow devices are smaller and may be more durable than the pulsatile-flow devices. METHODS In this randomized trial, we enrolled patients with advanced heart failure who were ineligible for transplantation, in a 2:1 ratio, to undergo implantation of a continuous-flow device… 

Figures and Tables from this paper

Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes

Outcome after LVAD implantation in stable patients is superior to that of ‘crash and burn’ patients or patients sliding on inotropes, favouring early referral and implantation, and current outcomes clearly justify use of LVADs in advanced HF.

Advances in Heart Failure Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices

The literature evaluating the prevalence, etiology, outcomes, and management of bleeding events in the LVAD population is summarized, and areas where more studies are necessary to guide future therapies and interventions are identified.

Durability of continuous-flow left ventricular assist devices: a systematic review.

With the expected rise in LVAD usage for end-stage heart failure, particularly as a DT, the steady minority of patients experiencing device failure is likely to increase and further investigation is required into the incidence and mechanism of major causes of failure, as well as design improvements that may address these complications.

Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy

The benefit of DT therapy with the HMII is confirmed in subsequent trial patients, with improved adverse event rates and a strong trend for improvements in survival.

Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications

  • H. Eisen
  • Medicine
    Korean circulation journal
  • 2019
Left ventricular assist devices (LVADs) offer an alternative that can improve survival as well as exercise tolerance and quality of life in patients with advanced heart failure and may offer an opportunity for long term survival in many patients.

Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review

There has been significant progress in nearly all aspects of left ventricular assist device therapy, from patient selection to device design and postoperative management, and there are many innovations now under investigation that promise to further improve outcomes and enhance patient satisfaction.

HeartMate® II continuous-flow left ventricular assist system

When directly compared with a pulsatile LVAD, the implantation of a HeartMate II LVAS resulted in an overall improvement in survival with a reduction in the number of device-related complications and adverse events.

Contemporary outcomes of continuous-flow left ventricular assist devices-a systematic review.

Outcomes after cf-LVAD implantation are excellent, with short-term survival comparable to heart transplantation, but long- term survival remains limited due to the incidence of post-implantation adverse events.

Advances in Mechanical Circulatory Support Quality of Life and Left Ventricular Assist Device Support

Quality of Life QOL is a subjective evaluation that reflects a person’s overall appraisal of how happy, satisfied, and content he or she is with life and can be measured indirectly with health status questionnaires or rating scales or described through qualitative research methodology.



Use of a continuous-flow device in patients awaiting heart transplantation.

A continuous-flow left ventricular assist device can provide effective hemodynamic support for a period of at least 6 months in patients awaiting heart transplantation, with improved functional status and quality of life.

Long-term use of a left ventricular assist device for end-stage heart failure.

The use of a left ventricular assist device in patients with advanced heart failure resulted in a clinically meaningful survival benefit and an improved quality of life.

Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device.

Outcomes of Left Ventricular Assist Device Implantation as Destination Therapy in the Post-REMATCH Era: Implications for Patient Selection

Outcomes of DT in the post-REMATCH era in the United States are described, finding that patients with advanced heart failure who are referred for DT before major complications of heart failure develop have the best chance of achieving an excellent 1-year survival with LVAD therapy.


In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy.

The effect of cardiac resynchronization on morbidity and mortality in heart failure.

In patients with heart failure and cardiac dyssynchrony, cardiac resynchronization improves symptoms and the quality of life and reduces complications and the risk of death.

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

In patients with advanced heart failure and a prolonged QRS interval, cardiac-resynchronization therapy decreases the combined risk of death from any cause or first hospitalization and, when combined with an implantable defibrillator, significantly reduces mortality.

Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure

CRT and CRT-D significantly improve time to all-cause mortality and hospitalizations in NYHA class IV patients, with a trend for improved mortality.

Stroke in patients with heart failure and reduced left ventricular ejection fraction

Whether warfarin is superior to aspirin in reducing stroke and mortality in patients with low ejection fraction is an important clinical issue that warrants prospective evaluation.